Amgen (AMGN) Misses Q1 EPS by 35c, Revenues Miss; Reaffirms FY21 EPS/Revenues Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PCVX
3. SPY
4. PTC
5. MSFT
6. META
7. AMD
8. GMAB
9. AMZN
10. ATH

Go back to Amgen (AMGN) Misses Q1 EPS by 35c, Revenues Miss; Reaffirms FY21 EPS/Revenues Guidance

Amgen Reports First Quarter 2021 Financial Results

April 27, 2021 4:01 PM EDT

THOUSAND OAKS, Calif., April 27, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2021. Key results include:

Total revenues decreased 4% to $5.9 billion in comparison to the first quarter of 2020, driven by lower net selling prices, partially offset by volume growth. These results reflect the cumulative, continuing negative effect of COVID-19 on patient visits and new patient diagnoses. Although product sales decreased 5%, volumes grew double digits or better for a number of products including Repatha® (evolocumab), Prolia® (denosumab), MVASI® (bevacizumab-awwb) and KANJINTI®... More